Nothing Special   »   [go: up one dir, main page]

SI3342785T1 - Povezovalci za konjugate protitelesa in zdravila - Google Patents

Povezovalci za konjugate protitelesa in zdravila

Info

Publication number
SI3342785T1
SI3342785T1 SI201331658T SI201331658T SI3342785T1 SI 3342785 T1 SI3342785 T1 SI 3342785T1 SI 201331658 T SI201331658 T SI 201331658T SI 201331658 T SI201331658 T SI 201331658T SI 3342785 T1 SI3342785 T1 SI 3342785T1
Authority
SI
Slovenia
Prior art keywords
linkers
antibody
drug conjugates
conjugates
drug
Prior art date
Application number
SI201331658T
Other languages
English (en)
Inventor
Takeshi Masuda
Hiroyuki Naito
Takashi Nakada
Masao Yoshida
Shinji Ashida
Hideki Miyazaki
Yuji Kasuya
Koji Morita
Yuki Abe
Yusuke Ogitani
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50477169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3342785(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Publication of SI3342785T1 publication Critical patent/SI3342785T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
SI201331658T 2012-10-11 2013-10-10 Povezovalci za konjugate protitelesa in zdravila SI3342785T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012225887 2012-10-11
EP18152381.2A EP3342785B1 (en) 2012-10-11 2013-10-10 Linkers for antibody-drug conjugates

Publications (1)

Publication Number Publication Date
SI3342785T1 true SI3342785T1 (sl) 2020-02-28

Family

ID=50477169

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201331658T SI3342785T1 (sl) 2012-10-11 2013-10-10 Povezovalci za konjugate protitelesa in zdravila
SI201331006T SI2907824T1 (sl) 2012-10-11 2013-10-10 Zdravilni konjugat protitelesa

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201331006T SI2907824T1 (sl) 2012-10-11 2013-10-10 Zdravilni konjugat protitelesa

Country Status (30)

Country Link
US (5) US10195288B2 (sl)
EP (3) EP3632471A1 (sl)
JP (9) JP5953378B2 (sl)
KR (14) KR102237639B1 (sl)
CN (4) CN115960111A (sl)
AU (4) AU2013328111B2 (sl)
BR (3) BR122021014365B1 (sl)
CA (2) CA3021435C (sl)
CY (2) CY1120363T1 (sl)
DK (2) DK3342785T3 (sl)
ES (2) ES2671644T3 (sl)
HK (2) HK1210477A1 (sl)
HR (2) HRP20180870T1 (sl)
HU (2) HUE048748T2 (sl)
IL (5) IL313147A (sl)
LT (2) LT2907824T (sl)
MX (3) MX364484B (sl)
MY (1) MY170251A (sl)
NZ (4) NZ705394A (sl)
PH (2) PH12015500667B1 (sl)
PL (2) PL3342785T3 (sl)
PT (2) PT2907824T (sl)
RS (2) RS57278B1 (sl)
RU (1) RU2664465C2 (sl)
SG (2) SG10201804788XA (sl)
SI (2) SI3342785T1 (sl)
TR (1) TR201809636T4 (sl)
TW (5) TWI696611B (sl)
WO (1) WO2014057687A1 (sl)
ZA (2) ZA201501825B (sl)

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102237639B1 (ko) 2012-10-11 2021-04-07 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트
WO2014061277A1 (ja) * 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
NZ721213A (en) * 2013-12-25 2022-12-23 Daiichi Sankyo Co Ltd Anti-trop2 antibody-drug conjugate
CN105829346B (zh) * 2014-01-31 2019-08-23 第一三共株式会社 抗her2抗体－药物偶联物
JP2017114763A (ja) * 2014-03-26 2017-06-29 第一三共株式会社 抗ｃｄ９８抗体−薬物コンジュゲート
ES2754348T3 (es) * 2014-04-10 2020-04-17 Daiichi Sankyo Co Ltd Conjugado de (anticuerpo anti-HER2)-fármaco
KR102445502B1 (ko) * 2014-04-10 2022-09-21 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
BR112017027690A2 (pt) 2015-06-29 2018-10-09 Daiichi Sankyo Co Ltd “método para produção de uma composição de conjugado anticorpo-fármaco, e, composição de conjugado anticorpo-fármaco
CN108779338A (zh) * 2015-12-24 2018-11-09 Ａｇｃ株式会社 树脂组合物、基材以及细胞培养方法
JP7002467B2 (ja) 2016-04-15 2022-01-20 マクロジェニクス，インコーポレーテッド 新規のｂ７‐ｈ３結合分子、その抗体薬物コンジュゲート、及びその使用方法
EP3468993A1 (en) * 2016-06-08 2019-04-17 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
IL300274A (en) * 2016-06-08 2023-04-01 Abbvie Inc Antibodies against B7–H3 and conjugates of drug and antibody
TW201825524A (zh) * 2016-09-20 2018-07-16 中國大陸商上海藥明生物技術有限公司 新型抗-pcsk9抗體
KR20190095280A (ko) 2016-12-12 2019-08-14 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트와 면역 체크 포인트 저해제의 조합
CA3050668C (en) * 2017-01-17 2023-08-15 Daiichi Sankyo Company, Limited Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
US20200061031A1 (en) 2017-02-28 2020-02-27 Kinki University Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate
TWI794230B (zh) 2017-05-15 2023-03-01 日商第一三共股份有限公司 抗ｃｄｈ６抗體及抗ｃｄｈ６抗體-藥物結合物、以及其製造方法
CN109963591B (zh) * 2017-08-04 2023-04-04 江苏恒瑞医药股份有限公司 B7h3抗体-药物偶联物及其医药用途
WO2019034176A1 (zh) * 2017-08-18 2019-02-21 四川百利药业有限责任公司 一种喜树碱-抗体偶联物
JP7204651B2 (ja) 2017-08-23 2023-01-16 第一三共株式会社 抗体－薬物コンジュゲートの製剤及びその凍結乾燥方法
CN117865839A (zh) 2017-08-31 2024-04-12 第一三共株式会社 制备抗体-药物缀合物的新方法
AU2018327171B2 (en) 2017-08-31 2023-03-09 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
IL301636B1 (en) 2017-09-29 2024-10-01 Daiichi Sankyo Co Ltd Conjugation of an antibody with a pyrrolobenzodiazepine derivative
CN111542324B (zh) * 2018-02-11 2023-09-12 四川科伦博泰生物医药股份有限公司 细胞毒性剂及其偶联物、其制备方法及用途
HUE063066T2 (hu) 2018-05-18 2024-01-28 Glycotope Gmbh ANTI-MUC1 antitest
CA3103629A1 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
BR112021001194A2 (pt) 2018-07-25 2021-04-27 Daiichi Sankyo Company, Limited métodos para produzir um conjugado anticorpo-fármaco e para produzir uma composição farmacêutica
EP3831853A4 (en) 2018-07-27 2022-06-01 Daiichi Sankyo Company, Limited ANTIBODY-DRUG CONJUGATE PROTEIN-RECOGNIZING DRUG UNIT
US20210290777A1 (en) 2018-07-31 2021-09-23 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of antibody-drug conjugate
CA3108754A1 (en) 2018-08-06 2020-02-13 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and tubulin inhibitor
TW202016317A (zh) 2018-08-23 2020-05-01 日商第一三共股份有限公司 抗體藥物結合物之感受性標記
JP7254818B2 (ja) 2018-09-06 2023-04-10 第一三共株式会社 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート
BR112021005246A2 (pt) 2018-09-20 2021-06-15 Daiichi Sankyo Company, Limited agente terapêutico, e, método de tratamento para câncer
US20210353764A1 (en) * 2018-09-26 2021-11-18 Jiangsu Hengrui Medicine Co., Ltd. Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof
US20210347894A1 (en) * 2018-09-30 2021-11-11 Jiangsu Hengrui Medicine Co., Ltd. Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof
EP3882349A4 (en) 2018-11-14 2023-04-05 Daiichi Sankyo Company, Limited (ANTI-CDH6 ANTIBODY)-(PYRROLOBENZODIAZEPINE DERIVATIVE) CONJUGATE
AU2019396895A1 (en) * 2018-12-11 2021-07-08 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with PARP inhibitor
CN113195000A (zh) * 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
WO2020191344A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
BR112021018608A2 (pt) 2019-03-20 2021-11-23 Univ California Anticorpos para claudina-6 e conjugados de fármaco
AU2020252034B2 (en) 2019-03-29 2024-02-01 Medimmune Limited Compounds and conjugates thereof
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
CN111689980A (zh) * 2019-05-26 2020-09-22 四川百利药业有限责任公司 一种喜树碱药物及其抗体偶联物
BR112021026580A2 (pt) * 2019-06-28 2022-05-03 Shanghai Fudan Zhangjiang Bio Pharmaceutical Co Ltd Conjugado anticorpo - fármaco, intermediário do mesmo, método de preparação e aplicação do mesmo
CN112138171B (zh) * 2019-06-28 2024-09-24 泰州复旦张江药业有限公司 抗体偶联药物、其中间体、制备方法及应用
CN114302744A (zh) 2019-07-10 2022-04-08 赛博克萨3公司 作为治疗剂的微管靶向剂的肽缀合物
US11634508B2 (en) 2019-07-10 2023-04-25 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
CN112125915A (zh) * 2019-09-18 2020-12-25 四川百利药业有限责任公司 一种喜树碱衍生物及其偶联物
CA3162754A1 (en) * 2019-12-12 2021-06-17 Jiangsu Hengrui Medicine Co., Ltd. Anti-claudin antibody-drug conjugate and pharmaceutical use thereof
CN114729035B (zh) * 2019-12-16 2024-04-16 江苏恒瑞医药股份有限公司 抗cea抗体-依喜替康类似物偶联物及其医药用途
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CA3168654A1 (en) 2020-01-22 2021-07-29 Shanghai Senhui Medicine Co., Ltd. Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine
TW202140077A (zh) 2020-01-22 2021-11-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｔｒｏｐ－２抗體－依喜替康類似物偶聯物及其醫藥用途
CA3168882A1 (en) 2020-02-25 2021-09-02 Mediboston, Inc. Camptothecin derivatives and conjugates thereof
CA3168368A1 (en) 2020-03-06 2021-09-10 Masayuki Ishizaki Antibody-drug conjugate including novel cyclic dinucleotide derivative
WO2021190480A1 (zh) * 2020-03-24 2021-09-30 上海翰森生物医药科技有限公司 抗体-药物偶联物及其医药用途
CA3175048A1 (en) 2020-03-25 2021-09-30 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Preparation method for antibody medicament conjugate
WO2021190583A1 (zh) * 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 抗psma抗体-依喜替康类似物偶联物及其医药用途
MX2022011770A (es) 2020-03-25 2022-10-18 Jiangsu Hengrui Pharmaceuticals Co Ltd Composicion farmaceutica que contiene un conjugado de anticuerpo-farmaco y uso de la misma.
US20240261424A1 (en) 2020-03-30 2024-08-08 National Cancer Center Antibody drug conjugate
JP2023529415A (ja) * 2020-06-08 2023-07-10 バイリ－バイオ（チェンドゥ）ファーマスーティカル シーオー．，エルティーディー． 高安定性の親水性結合ユニットを有するカンプトテシン類薬物及びその複合体
WO2021260580A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atm inhibitor
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
CA3183867A1 (en) 2020-06-24 2021-12-30 Jerome Thomas Mettetal Ii Combination of antibody-drug conjugate and atr inhibitor
US20230233540A1 (en) 2020-06-24 2023-07-27 Astrazeneca Uk Limited Combination of antibody-drug conjugate and cdk9 inhibitor
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
US10997243B1 (en) 2020-06-30 2021-05-04 Snowflake Inc. Supporting unstructured, semi-structured, and structured files
US11361026B2 (en) 2020-06-30 2022-06-14 Snowflake Inc. Accessing files in a database stage using a user defined function
US11423081B1 (en) 2020-06-30 2022-08-23 Snowflake Inc. Accessing files in a database stage using a user defined function
KR20230035332A (ko) 2020-07-06 2023-03-13 비온디스 비.브이. 항엽산제 링커-약물 및 항체-약물 접합체
EP4178559A1 (en) * 2020-07-10 2023-05-17 Velosbio Inc. Novel ror1 antibody immunoconjugates
KR20230038738A (ko) * 2020-07-13 2023-03-21 리제너론 파마슈티칼스 인코포레이티드 단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도
WO2022014698A1 (ja) 2020-07-17 2022-01-20 第一三共株式会社 抗体－薬物コンジュゲートの製造方法
WO2022033578A1 (zh) * 2020-08-13 2022-02-17 正大天晴药业集团股份有限公司 抗体药物偶联物
JP2023537115A (ja) 2020-08-13 2023-08-30 イナート・ファルマ・ソシエテ・アノニム 抗ｃｄ７３抗体を使用する癌処置方法
WO2022050300A1 (ja) 2020-09-02 2022-03-10 第一三共株式会社 新規エンド－β－Ｎ－アセチルグルコサミニダーゼ
CN116199739A (zh) 2020-09-30 2023-06-02 映恩生物制药（苏州）有限公司 一种抗肿瘤化合物及其制备方法和应用
AU2021356762A1 (en) 2020-10-09 2023-05-25 Astrazeneca Uk Limited Combination of antibody-drug conjugate and parp1 selective inhibitor
AU2021359457A1 (en) * 2020-10-12 2023-05-11 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Camptothecin derivative and its ligand-drug conjugate
IL302812A (en) 2020-11-11 2023-07-01 Daiichi Sankyo Co Ltd Antibody-drug conjugate combinations with anti-SIRP alpha antibody
EP4245322A1 (en) 2020-11-12 2023-09-20 Daiichi Sankyo Company, Limited Treatment for mesothelioma through administration of anti-b7-h3 antibody-drug conjugate
WO2022099762A1 (zh) * 2020-11-12 2022-05-19 博瑞生物医药（苏州）股份有限公司 一种抗体偶联物中间体及其制备方法
EP4265274A4 (en) * 2020-12-18 2024-03-20 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. ANTIBODY-ACTIVE CONJUGATE DIRECTED AGAINST B7-H3 AND PRODUCTION METHOD THEREOF AND USE THEREOF
EP4265275A4 (en) * 2020-12-18 2024-03-20 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. ANTIBODY-DRUG CONJUGATE TARGETING TROP2, PREPARATION METHOD AND USE THEREOF
WO2022140504A1 (en) * 2020-12-23 2022-06-30 Shanghai Ruotuo Biosciences Co., Ltd. Antibody-drug conjugates, pharmaceutical compositions, and therapeutic applications
WO2022153195A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate
CN114805377A (zh) * 2021-01-29 2022-07-29 明慧医药（杭州）有限公司 适用于抗体-药物偶联物的毒素分子
TW202241454A (zh) 2021-02-01 2022-11-01 日商第一三共股份有限公司 抗體－免疫賦活化劑共軛物之新穎製造方法
TW202241521A (zh) 2021-02-09 2022-11-01 大陸商蘇州宜聯生物醫藥有限公司 生物活性物偶聯物及其製備方法和用途
BR112023017365A2 (pt) 2021-03-12 2023-10-03 Daiichi Sankyo Co Ltd Glicano e método para produzir medicamento contendo glicano
WO2022194257A1 (zh) * 2021-03-17 2022-09-22 江苏恒瑞医药股份有限公司 一种喜树碱衍生物的制备方法
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
AU2022246895A1 (en) 2021-03-31 2023-10-19 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
CA3215049A1 (en) 2021-04-10 2022-10-13 Baiteng ZHAO Folr1 binding agents, conjugates thereof and methods of using the same
AU2022259314A1 (en) * 2021-04-14 2023-11-30 Genequantum Healthcare (Suzhou) Co., Ltd. Linkers, conjugates and applications thereof
EP4079327A1 (en) 2021-04-22 2022-10-26 Centaurus Polytherapeutics Payloads for drug-conjugates and their use for treating cancer
TW202308699A (zh) 2021-04-23 2023-03-01 美商普方生物製藥美國公司 Ｃｄ７０結合劑、其結合物及其使用方法
MX2023012456A (es) * 2021-04-26 2023-10-31 Jiangsu Hengrui Pharmaceuticals Co Ltd Anticuerpo anti-nectina-4 y conjugado anticuerpo-farmaco anti-nectina-4-, y uso medicinal del mismo.
CN113816969B (zh) * 2021-04-30 2024-01-16 联宁（苏州）生物制药有限公司 依喜替康类化合物、其抗体药物偶联物及其应用
US11645243B2 (en) 2021-06-07 2023-05-09 Snowflake Inc. Accessing files in a database stage using a user defined function
CA3223304A1 (en) * 2021-06-17 2022-12-22 Minghui Pharmaceutical (Hangzhou) Limited Antitumor compound and its application
JP2024524363A (ja) 2021-06-28 2024-07-05 ビョンディス・ビー．ブイ． ホスホ抗原を含む複合体及び治療における使用
JP2024525475A (ja) 2021-06-29 2024-07-12 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションを促進するように操作された免疫細胞及びその使用
CN113402584A (zh) * 2021-07-06 2021-09-17 联宁（苏州）生物制药有限公司 一种抗体偶联药物连接子的中间体lnd1067-l1的合成方法
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
CN113527418B (zh) * 2021-07-16 2022-05-03 成都普康唯新生物科技有限公司 一种ADC linker的制备方法
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
AU2022315277A1 (en) * 2021-07-19 2024-01-18 Zeno Management, Inc. Immunoconjugates and methods
CN117337191A (zh) 2021-07-21 2024-01-02 江苏恒瑞医药股份有限公司 一种含抗trop2抗体药物偶联物的药物组合物及其用途
MX2024003277A (es) 2021-09-15 2024-04-04 Daiichi Sankyo Co Ltd Conjugado de anticuerpo-farmaco para usarse en metodos de tratamiento del cancer resistente a la quimioterapia.
KR20240073035A (ko) 2021-09-30 2024-05-24 아지노모토 가부시키가이샤 항체 및 기능성 물질의 컨쥬게이트 또는 그 염, 및 그 제조에 사용되는 항체 유도체 및 화합물 또는 그 염
CA3235358A1 (en) 2021-10-18 2023-04-27 Daiichi Sankyo Company, Limited Anti-cd37 antibody-drug conjugate
KR20240101682A (ko) 2021-11-15 2024-07-02 시스트이뮨, 인코포레이티드 이중특이 항체-캄프토테신 약물 접합체 및 이의 약학적 용도
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
CN118414173A (zh) 2021-11-18 2024-07-30 阿斯利康(英国)有限公司 抗体-药物缀合物和parp1选择性抑制剂的组合
EP4433096A1 (en) 2021-11-19 2024-09-25 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same
JPWO2023100829A1 (sl) 2021-11-30 2023-06-08
KR20240112954A (ko) 2021-12-03 2024-07-19 시스트이뮨, 인코포레이티드 항-인간 trop2 항체-캄프토테신 약물 접합체 및 이의 의학적 용도
CA3240378A1 (en) 2021-12-23 2023-06-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-dll3 antibody and pharmaceutical use thereof, and antibody-drug conjugate containing anti-dll3 antibody
WO2023116911A1 (zh) * 2021-12-24 2023-06-29 百奥泰生物制药股份有限公司 抗FRα抗体及其抗体药物偶联物和用途
KR20240130087A (ko) 2021-12-28 2024-08-28 아스트라제네카 유케이 리미티드 항체-약물 접합체와 atr 저해제의 조합
TW202333800A (zh) 2021-12-28 2023-09-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及rasg12c抑制劑之組合
IL313806A (en) 2021-12-30 2024-08-01 Byondis Bv Antifolate binding drugs and antidrug conjugates
WO2023138635A1 (zh) * 2022-01-18 2023-07-27 甘李药业股份有限公司 一种依喜替康衍生物-抗体偶联物及其医药用途
KR20240137076A (ko) 2022-01-25 2024-09-19 메디링크 테라퓨틱스 (쑤저우) 컴퍼니, 리미티드 Her3에 대한 항체, 접합체 및 이의 용도
IL314707A (en) 2022-02-09 2024-10-01 Daiichi Sankyo Co Ltd Environmentally reactive masked antibody and its use
JPWO2023163234A1 (sl) 2022-02-28 2023-08-31
AU2023226367A1 (en) 2022-02-28 2024-10-03 Ube Corporation Antibody-drug conjugate
CN118804983A (zh) 2022-03-02 2024-10-18 第一三共株式会社 含Fc分子的制造方法
WO2023173026A1 (en) 2022-03-10 2023-09-14 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
CN118891525A (zh) 2022-03-16 2024-11-01 阿斯利康(英国)有限公司 用于抗trop2抗体-药物缀合物疗法的评分方法
TW202342025A (zh) 2022-03-18 2023-11-01 大陸商映恩生物製藥（蘇州）有限公司 Gpc3抗體藥物偶聯物及其用途
AU2023262308A1 (en) 2022-04-27 2024-10-03 Astrazeneca Uk Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
WO2023218378A1 (en) 2022-05-11 2023-11-16 Daiichi Sankyo Company, Limited Combination of an antibody specific for a tumor antigen and a cd47 inhibitor
WO2023228095A1 (en) 2022-05-24 2023-11-30 Daiichi Sankyo Company, Limited Dosage regimen of an anti-cdh6 antibody-drug conjugate
WO2023237050A1 (en) * 2022-06-09 2023-12-14 Beigene, Ltd. Antibody drug conjugates
WO2024008102A1 (en) * 2022-07-05 2024-01-11 Wuxi Xdc (Shanghai) Co., Ltd. Linker for conjugation
CN115160403A (zh) * 2022-07-05 2022-10-11 上海彩迩文生化科技有限公司 特异性拓扑异构酶抑制剂和可用于抗体药物偶联物及其制备方法
WO2024012566A2 (en) 2022-07-15 2024-01-18 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody, linkers, payload, conjugates and applications thereof
WO2024020536A1 (en) * 2022-07-22 2024-01-25 Nj Bio, Inc. Hexacyclic topoisomerase inhibitors having cytotoxic activity on cancer cells
WO2024022372A1 (zh) * 2022-07-27 2024-02-01 明慧医药（杭州）有限公司 抗体药物偶联物及其应用
WO2024023750A1 (en) 2022-07-28 2024-02-01 Astrazeneca Uk Limited Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
CN117510515A (zh) * 2022-07-28 2024-02-06 明慧医药（杭州）有限公司 适用于抗体-药物偶联物的毒素分子
WO2024049931A1 (en) 2022-09-02 2024-03-07 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
WO2024073436A2 (en) * 2022-09-26 2024-04-04 Solve Therapeutics, Inc. Compositions and uses thereof
WO2024067811A1 (en) * 2022-09-30 2024-04-04 Beigene, Ltd. Ligand-drug conjugate of exatecan analogue, and medical use thereof
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024091437A1 (en) 2022-10-25 2024-05-02 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
WO2024110905A1 (en) 2022-11-24 2024-05-30 Beigene, Ltd. Anti-cea antibody drug conjugates and methods of use
WO2024109949A1 (zh) * 2022-11-25 2024-05-30 明慧医药（杭州）有限公司 一种抗肿瘤化合物及其应用
WO2024114318A1 (zh) * 2022-11-29 2024-06-06 四川科伦博泰生物医药股份有限公司 药物连接子化合物及其制备方法和用途
WO2024116094A1 (en) 2022-11-30 2024-06-06 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugates and dnmt inhibitors
CN116621927B (zh) * 2023-01-09 2024-03-26 联宁（苏州）生物制药有限公司 带有伊喜替康和C-lock定点偶联基团的抗体偶联中间体、偶联方法及抗体偶联药物
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024165045A1 (en) 2023-02-09 2024-08-15 Beigene, Ltd. Self-stabilizing linker conjugates
WO2024179470A1 (zh) * 2023-02-27 2024-09-06 苏州盛迪亚生物医药有限公司 抗dll3抗体、其抗体-药物偶联物及其医药用途
CN118666946A (zh) * 2023-03-15 2024-09-20 上海亲合力生物医药科技股份有限公司 连接子及使用其的偶联药物、抗体偶联药物及其应用
WO2024194851A1 (en) * 2023-03-23 2024-09-26 Beigene Switzerland Gmbh Bioactive conjugate, preparation method therefor and use thereof
WO2024211236A2 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024211234A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024211235A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024213091A1 (en) 2023-04-13 2024-10-17 Genequantum Healthcare (Suzhou) Co., Ltd. Combination of antibody-drug conjugate and anti-pd-1 antibody, and use thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
US5658920A (en) * 1991-01-16 1997-08-19 Daiichi Pharmaceutical Co., Ltd. Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound
JP3008226B2 (ja) 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
JPH0559061U (ja) 1991-04-18 1993-08-03 株式会社ケイヴイシー ボールバルブ
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JP3359955B2 (ja) 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JPH0687746U (ja) 1993-06-02 1994-12-22 株式会社ユニシアジェックス 液圧緩衝器のリザーバチューブ構造
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
CA2177367A1 (en) 1993-12-03 1995-06-08 Andrew David Griffiths Recombinant binding proteins and peptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
JPH08337584A (ja) 1995-04-10 1996-12-24 Dai Ichi Seiyaku Co Ltd 縮合六環式アミノ化合物、これを含有する医薬及びその製法
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CA2192725C (en) 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
JPH1095802A (ja) 1995-12-28 1998-04-14 Tanabe Seiyaku Co Ltd カンプトテシン誘導体
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
JPH1171280A (ja) 1997-06-26 1999-03-16 Tanabe Seiyaku Co Ltd 医薬組成物
JPH1192405A (ja) 1997-09-19 1999-04-06 Dai Ichi Seiyaku Co Ltd 薬物複合体
EP1071700B1 (en) 1998-04-20 2010-02-17 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
WO1999061061A1 (fr) * 1998-05-22 1999-12-02 Daiichi Pharmaceutical Co., Ltd. Composites medicamenteux
ID29943A (id) 1998-10-30 2001-10-25 Daiichi Seiyaku Co Senyawa dds dan metode pengukurannya
EP2270150B2 (en) 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
JP2002060351A (ja) 2000-03-22 2002-02-26 Dai Ichi Seiyaku Co Ltd 水酸基を有する薬物を含むｄｄｓ化合物
CA2412582A1 (en) * 2000-06-29 2002-01-03 Daiichi Pharmaceutical Co., Ltd. Dds compound and process for the preparation thereof
CA2415922A1 (en) 2000-07-13 2002-01-24 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical compositions containing dds compound
CN1894406A (zh) 2000-10-06 2007-01-10 协和发酵工业株式会社 产生抗体组合物的细胞
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
TWI313609B (en) 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
AU2002360307B2 (en) 2001-11-01 2008-01-17 The Uab Research Foundation Combinations of DR5 antibody and other therapeutic agents
CA2467242A1 (en) * 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
EP1572242B1 (en) 2002-12-13 2014-04-16 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
EP1722797A4 (en) 2004-02-26 2008-03-19 Inotek Pharmaceuticals Corp ISOCHINOLINE DERIVATIVES AND METHOD FOR THE APPLICATION THEREOF
WO2005084390A2 (en) 2004-03-02 2005-09-15 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
MXPA06013413A (es) * 2004-05-19 2007-01-23 Medarex Inc Enlazadores quimicos y conjugados de los mismos.
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
CA2587589A1 (en) 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
DE102005009099A1 (de) 2005-02-28 2006-08-31 Ktb Tumorforschungsgesellschaft Mbh Proteinbindende Camptothecin-Peptid-Derivate und diese enthaltende Arzneimittel
DE102005009084A1 (de) 2005-02-28 2006-08-31 Ktb Tumorforschungsgesellschaft Mbh Proteinbindende Anthrazyklin-Peptid-Derivate und diese enthaltende Arzneimittel
EP1871418B1 (en) 2005-04-19 2014-03-19 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
ES2567402T3 (es) * 2006-05-30 2016-04-22 Genentech, Inc. Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos
CN101490087B (zh) 2006-05-30 2013-11-06 健泰科生物技术公司 抗体和免疫偶联物及其用途
WO2007145306A1 (ja) 2006-06-15 2007-12-21 National University Corporation Hokkaido University 腫瘍組織で選択的に分解性を示す血中滞留性素子
ITMI20061473A1 (it) 2006-07-26 2008-01-27 Indena Spa Derivati della camptotecina ad attivita antitumorale
EP2109607A1 (en) 2006-12-21 2009-10-21 Schering Corporation Pyrrolo[3, 2-a]pyridine derivatives for inhibiting ksp kinesin activity
JP2010523478A (ja) * 2007-03-22 2010-07-15 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ モノクローナル抗体８ｈ９の使用
CN104524592B (zh) 2008-04-30 2018-06-05 伊缪诺金公司 交联剂和它们的用途
CA2749501C (en) 2009-02-13 2017-01-10 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
WO2011021397A1 (ja) 2009-08-20 2011-02-24 国立大学法人千葉大学 コルヒチン誘導体
US20110070248A1 (en) 2009-09-24 2011-03-24 Seattle Genetics, Inc. Dr5 ligand drug conjugates
KR20130062931A (ko) 2010-05-13 2013-06-13 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 핵 호르몬 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
EP2571525A4 (en) 2010-05-18 2016-04-27 Cerulean Pharma Inc Compositions and methods for treating autoimmune and other diseases
EP2593142B8 (en) 2010-07-12 2018-12-26 Pfizer Healthcare Ireland Multifunctional antibody conjugates
CN103313990B (zh) 2010-11-17 2016-07-20 基因泰克公司 丙氨酰美登醇抗体偶联物
RU2014128467A (ru) 2011-12-14 2016-02-10 Сиэтл Дженетикс, Инк. Новые коньюгаты связывающее соединение-активное соединение (adc) и их применение
US20130280282A1 (en) 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
CA2876706A1 (en) 2012-06-14 2013-12-19 Ambrx, Inc. Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
US9517522B2 (en) * 2012-09-05 2016-12-13 Illinois Tool Works Inc. Self-aligning wire feeder assembly
KR102237639B1 (ko) 2012-10-11 2021-04-07 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
CN105051032B (zh) 2013-01-03 2017-08-15 赛特瑞恩股份有限公司 抗体‑连接子‑药物偶联物、其制法及包含其的抗癌药物组合物
CN103313390B (zh) 2013-07-05 2016-01-20 江苏大学 一种基于双移动信标的wsn定位方法
CN105829346B (zh) * 2014-01-31 2019-08-23 第一三共株式会社 抗her2抗体－药物偶联物
ES2754348T3 (es) 2014-04-10 2020-04-17 Daiichi Sankyo Co Ltd Conjugado de (anticuerpo anti-HER2)-fármaco
KR102199434B1 (ko) 2017-02-24 2021-01-06 장길훈 대화형 애플리케이션의 메시지 공유 시스템과 방법

Also Published As

Publication number Publication date
TW201920098A (zh) 2019-06-01
NZ746440A (en) 2019-11-29
PH12018501433A1 (en) 2019-02-27
KR20230086800A (ko) 2023-06-15
CA2885800C (en) 2018-12-04
EP2907824B1 (en) 2018-04-11
HK1210477A1 (en) 2016-04-22
DK2907824T3 (en) 2018-07-23
JP6030267B1 (ja) 2016-11-24
TR201809636T4 (tr) 2018-07-23
MX364484B (es) 2019-04-29
HUE048748T2 (hu) 2020-08-28
CN113929738A (zh) 2022-01-14
JP2018188455A (ja) 2018-11-29
KR20220100727A (ko) 2022-07-15
CN104755494A (zh) 2015-07-01
MY170251A (en) 2019-07-13
TWI696611B (zh) 2020-06-21
KR20210132240A (ko) 2021-11-03
PH12015500667A1 (en) 2015-05-18
EP2907824A1 (en) 2015-08-19
AU2020200548A1 (en) 2020-02-13
CY1120363T1 (el) 2019-07-10
JP7170812B2 (ja) 2022-11-14
JP2020180124A (ja) 2020-11-05
IL238143A0 (en) 2015-05-31
KR101841818B1 (ko) 2018-03-26
JP2016196484A (ja) 2016-11-24
KR102320907B1 (ko) 2021-11-02
KR102498405B1 (ko) 2023-02-09
IL302494A (en) 2023-06-01
TWI615152B (zh) 2018-02-21
RS60000B1 (sr) 2020-04-30
IL313147A (en) 2024-07-01
TW201420117A (zh) 2014-06-01
IL294622B2 (en) 2023-10-01
JP2024147681A (ja) 2024-10-16
TW202233186A (zh) 2022-09-01
RU2018128384A3 (sl) 2021-12-20
PL3342785T3 (pl) 2020-09-07
JP5953378B2 (ja) 2016-07-20
JP6952835B2 (ja) 2021-10-27
KR20220029776A (ko) 2022-03-08
IL271760A (en) 2020-02-27
EP2907824A4 (en) 2016-06-08
RU2018128384A (ru) 2018-10-02
BR112015006521B1 (pt) 2022-03-03
HUE039000T2 (hu) 2018-12-28
CY1122789T1 (el) 2021-05-05
KR20210038728A (ko) 2021-04-07
TW201811746A (zh) 2018-04-01
KR20180105271A (ko) 2018-09-27
AU2018200308B2 (en) 2019-11-07
BR122021014396B1 (pt) 2022-07-05
EP3342785A1 (en) 2018-07-04
JP2022008581A (ja) 2022-01-13
LT3342785T (lt) 2020-02-10
DK3342785T3 (da) 2020-03-23
ZA201501825B (en) 2022-05-25
MX2015003903A (es) 2015-07-17
PT3342785T (pt) 2020-02-25
ES2671644T3 (es) 2018-06-07
KR102369419B1 (ko) 2022-03-02
TWI757740B (zh) 2022-03-11
US11633493B2 (en) 2023-04-25
MX2019004502A (es) 2019-08-21
CN109081871B (zh) 2023-07-14
CA3021435C (en) 2021-10-12
KR102709509B1 (ko) 2024-09-24
NZ705394A (en) 2018-10-26
LT2907824T (lt) 2018-06-11
KR20220146669A (ko) 2022-11-01
JP2018008982A (ja) 2018-01-18
NZ740948A (en) 2019-11-29
KR102087017B1 (ko) 2020-03-10
WO2014057687A1 (ja) 2014-04-17
KR101901558B1 (ko) 2018-09-21
IL271760B (en) 2022-08-01
SG10201804788XA (en) 2018-07-30
BR112015006521A2 (sl) 2017-09-05
BR122021014365B1 (pt) 2022-07-05
CN115960111A (zh) 2023-04-14
AU2013328111A1 (en) 2015-03-12
KR20230024433A (ko) 2023-02-20
KR20200026323A (ko) 2020-03-10
SI2907824T1 (sl) 2018-06-29
US20160279259A1 (en) 2016-09-29
NZ746439A (en) 2019-11-29
JP6715888B2 (ja) 2020-07-01
HK1256631A1 (zh) 2019-09-27
KR20150067149A (ko) 2015-06-17
KR20230142808A (ko) 2023-10-11
KR20240144454A (ko) 2024-10-02
CN109081871A (zh) 2018-12-25
US20200282073A1 (en) 2020-09-10
IL302494B1 (en) 2024-07-01
IL238143B (en) 2020-01-30
ZA201900820B (en) 2022-08-31
CN104755494B (zh) 2018-09-07
JP6371452B2 (ja) 2018-08-08
JP6186045B2 (ja) 2017-08-23
US20190008981A1 (en) 2019-01-10
KR20180030734A (ko) 2018-03-23
ES2773710T3 (es) 2020-07-14
JP2017036274A (ja) 2017-02-16
US10973924B2 (en) 2021-04-13
JPWO2014057687A1 (ja) 2016-09-05
SG11201502887WA (en) 2015-05-28
KR102237639B1 (ko) 2021-04-07
HRP20180870T1 (hr) 2018-07-13
KR20190135559A (ko) 2019-12-06
TW202033499A (zh) 2020-09-16
EP3632471A1 (en) 2020-04-08
US10195288B2 (en) 2019-02-05
IL302494B2 (en) 2024-11-01
KR102417310B1 (ko) 2022-07-05
MX2020010964A (es) 2020-11-09
AU2013328111B2 (en) 2017-11-02
PH12015500667B1 (en) 2015-05-18
JP7523506B2 (ja) 2024-07-26
JP2023011799A (ja) 2023-01-24
TWI650312B (zh) 2019-02-11
US20240082413A1 (en) 2024-03-14
KR102052319B1 (ko) 2019-12-05
KR102540419B1 (ko) 2023-06-05
KR102456726B1 (ko) 2022-10-20
PT2907824T (pt) 2018-06-07
CA3021435A1 (en) 2014-04-17
HRP20200353T1 (hr) 2020-06-12
PL2907824T3 (pl) 2018-08-31
KR102584005B1 (ko) 2023-09-27
RU2664465C2 (ru) 2018-08-17
CN113929738B (zh) 2024-05-17
IL294622B1 (en) 2023-06-01
US9808537B2 (en) 2017-11-07
CA2885800A1 (en) 2014-04-17
EP3342785B1 (en) 2019-12-25
RS57278B1 (sr) 2018-08-31
US20150297748A1 (en) 2015-10-22
IL294622A (en) 2022-09-01
RU2015113767A (ru) 2016-12-10
AU2020200548B2 (en) 2022-08-25
AU2018200308A1 (en) 2018-02-01
AU2022203560A1 (en) 2022-06-16

Similar Documents

Publication Publication Date Title
HK1256631A1 (zh) 用於抗體－藥物偶聯物的接頭
HUS2300020I1 (hu) Pirrolobenzodiazepin-antitest konjugátumok
SG10201605401WA (en) Antibody-drug conjugates
ZA201502523B (en) Pyrrolobenzodiazepine-anitbody conjugates
HK1207388A1 (en) Self-stabilizing linker conjugates
ZA201501996B (en) Drug-protein conjugates
IL237672B (en) Drug-protein conjugates